Novotech Report Reveals Global Surge in Infectious Disease Trials as Industry Nears 2,000 Studies Since 2020
Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development, has released a new report analyzing the evolving infectious disease clinical trial landscape. This report provides critical strategic insights for pharmaceutical and biotech companies navigating the complexities of global infectious disease research and development in 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250402008700/en/
Navigating the Future of Infectious Disease Clinical Trials
Between 2020 and 2024, the infectious disease clinical trial sector experienced significant global growth, with nearly 2,000 industry-sponsored trials initiated, ongoing, or planned. The Asia-Pacific region is leading this expansion with a 70% compound annual growth rate (CAGR), driven by strong government support and global partnerships. North America follows with a 52% CAGR, fueled by substantial biotech investment. Europe and the rest of the world continue to show steady progress, contributing to a geographically diverse and increasingly robust global clinical trial landscape.
Key findings:
- Global Clinical Trial Growth: Asia-Pacific dominates with 43% of global infectious disease trials, followed by North America (21%), Europe (20%), and ROW (16%).
- Therapeutic Focus Areas: Over 900 trials focused on viral infections such as COVID-19, HIV/AIDS, hepatitis B, and RSV, while bacterial and protozoal infections remain key research priorities.
- Technological Innovations: AI-driven drug discovery has accelerated development timelines by 60-70%, with decentralized clinical trials (DCTs) improving patient recruitment and retention.
- Antimicrobial Resistance (AMR) Challenge: AMR remains a critical public health threat, with limited industry investment slowing the development of novel antibiotics.
- Regulatory Harmonization & Platform Trials: Efforts such as WHO Prequalification programs and reliance pathways are expediting drug approvals, while platform trials are enhancing trial efficiency and cost-effectiveness.
Addressing Industry Challenges & Opportunities
While innovation in mRNA technology, gene-based therapies, and AI-driven drug discovery are advancing the treatment landscape for infectious disease, funding gaps continue to hinder antimicrobial research and neglected tropical disease (NTD) trials. Addressing these disparities through regulatory frameworks and strategic investment are essential to unlocking future innovation and ensuring sustainable growth across the global clinical trial ecosystem.
Novotech: A Trusted Partner in Infectious Disease Clinical Development
With deep therapeutic and regulatory expertise and an expansive global footprint across the Asia-Pacific region, North America, and Europe, Novotech supports biotech and pharmaceutical companies in accelerating infectious disease clinical development.
About NovotechNovotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402008700/en/
Contacts
Media Contact
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clean Tech Leader Aymium Defeats Stora Enso at European Patent Office Boards of Appeal4.4.2025 01:07:00 EEST | Press release
Cleantech leader Aymium defeated a challenge by Stora Enso to one of Aymium's patents (European Patent EP2697185) that provides exclusive rights to produce, sell and use bio-based materials for renewable battery applications. In its written opinion, the Boards of Appeal of the European Patent Office found Stora Enso's arguments brought before the board “not convincing” and agreed that a clarifying amendment to the claims did not extend the scope of protection of the patent. The ruling further affirms Aymium's position as the global leader in biocarbon materials for battery applications. Beyond the present ruling, Aymium owns a portfolio of more than 600 patents relating to biocarbon materials, compositions and manufacturing methods, including many specifically relevant to battery materials, and is the dominant global innovator regarding biocarbon materials. The ruling, combined with Aymium's massive patent portfolio, calls into question the ability of Stora Enso to produce bio-based ba
Esri Helps Bring Up-to-Date Road Closure Information To Consumer Mapping Apps4.4.2025 00:24:00 EEST | Press release
Esri, the global leader in GIS technology and location intelligence, has enhanced its popular Community Maps Program to make sharing of road closures much easier with the Road Closures solution. This new solution in Esri's ArcGIS, the leading and most comprehensive geospatial platform, bridges the gap between government agencies managing timely road updates and the public, who rely on mapping apps for real-time navigation. Thousands of Esri's ArcGIS software users — including state and local governments and national mapping agencies — create and share authoritative, accurate road data through the Esri Community Maps Program, and now they can share live road closure data as well. Esri ArcGIS users can now easily share road closure updates directly with consumer mapping providers including Apple Maps and TomTom, so they can update their maps with this important information. "Through the Esri Community Maps Program, we've been assembling authoritative data about city infrastructure from t
smartTrade Announces Strategic Investment from TA alongside CEO and Management3.4.2025 19:37:00 EEST | Press release
smartTrade Technologies (“smartTrade”), a leading global provider of multi-asset electronic trading and payments platforms, today announced a strategic investment from TA Associates (“TA”), a leading global private equity firm. David Vincent, CEO and Co-Founder of smartTrade, and the broader management team, would invest alongside TA at closing, reinforcing their shared commitment to the company’s future. Headquartered in Aix-en-Provence, France, with subsidiaries in London, Paris, Geneva, New York, Toronto, Tokyo and Singapore, smartTrade empowers customers to grow their electronic trading and payments business through secure, cost-efficient and technologically advanced end-to-end SaaS solutions. TA’s investment would support continued product innovation, geographic expansion and scalable growth, with a particular emphasis on AI-driven solutions and deployment flexibility. Upon completion of the transaction, Hg, a leading investor in European and transatlantic software and services bu
Barilla Ranks as the First Food Company in the World for Reputation in the 2025 Global RepTrak ® 1003.4.2025 18:59:00 EEST | Press release
Barilla Group is proud to announce its rise in the Global RepTrak® 100 rankings, emerging as the leading company in the food sector two years running. The company has secured the 25th position worldwide, moving up four spots compared to 2024, where it held the 29th position. This result, achieved thanks to the efforts of the Group’s people worldwide, reflects its continued focus on the quality of its products and services, inclusion, innovation, and willingness to bring people together through good food. With a presence in over 100 countries and 30 production sites (15 in Italy and 15 abroad), Barilla Group produces more than 2 million tons of products each year. Since 2010, it has reformulated nearly 500 products to improve their nutritional profile, reducing fats, saturated fats, salt, and sugar, or increasing fiber content. Aligned with its commitment to fostering inclusivity, in France the company has achieved a 100% score on the Professional Gender Equality Index1 this year, an in
Antognolla CEO: Rising Demand for Branded Residences in Mediterranean Driven by Lifestyle Shift among High-Net-Worth Individuals3.4.2025 17:27:00 EEST | Press release
Demand for branded residences in the Mediterranean is expected to rise as high-net-worth individuals change their lifestyle preferences, says Antognolla Resort and Residences’ CEO, Federico Ricci. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407645308/en/ Antognolla Castle - (Credit: Antognolla Resort and Residences) Mr Ricci made his comments after attending the International Hospitality Investment Forum EMEA, held in Berlin from 31 March to 2 April. This year’s forum focused on the rapidly evolving hospitality investment landscape and the changing definition of luxury for both guests and investors. “Discussions with other industry leaders have only reaffirmed our insights regarding the shift in the behavioural patterns of our customers,” said Mr Ricci. “This shift is more than just a passing trend; it reflects a deeper change in how people choose to live and invest in property. The pandemic accelerated the rise of rem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom